How to Check Avience Biomedicals IPO Allotment Status

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specialising in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.

The company has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. Its products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the company also acts as a distributor and trader of medical equipment.

Its product portfolio spans Rapid Test Kits (such as AVISURE Dengue Combo Test, Malaria Rapid Test, and AVISURE Syphilis Rapid Test), Biochemistry Analyzers and Reagents, Molecular Diagnostics (including COVID-19 detection kits), Hematology Analyzers, and Medical Devices (including oxygen concentrators and viral transport solutions). The company's manufacturing unit is situated in Noida, Uttar Pradesh. As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees.

Avience Biomedicals IPO is a book build issue of ₹30.24 crore, entirely comprising a fresh issue of 0.15 crore shares aggregating to ₹30.24 crore. The IPO opened on June 18, 2026, and closed on June 22, 2026. The allotment is expected on Tuesday, June 23, 2026. The share price band was set at ₹196 to ₹208 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Avience Biomedicals IPO Allotment Status on Registrar Site

• Visit the Skyline Financial Services Pvt. Ltd.
• Select "Avience Biomedicals" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Avience Biomedicals IPO Allotment Status on NSE

• Navigate to the NSE SME IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Avience Biomedicals" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Avience Biomedicals IPO subscribed 385.05 times overall. Here is the category-wise breakdown as of 4:55:00 PM on June 22, 2026:

Avience Biomedicals IPO Subscription Status

• QIB Category (Ex Anchor): 196.77 times
• Non-Institutional Investors (NII): 597.21 times
• Individual Investors: 400.84 times

Avience Biomedicals IPO Share Price and Investment Details

The minimum investment required was ₹2,49,600 for 2 lots (1,200 shares) for individual investors. The issue raised ₹8.52 crore from anchor investors. The issue includes a reservation of up to 82,200 shares for the market maker, Asnani Stock Broker Pvt. Ltd. The anchor investor lock-in period ends on July 23, 2026 for 50% of shares (30 days) and September 21, 2026 for the remaining shares (90 days). Given the overall subscription of 385.05 times with exceptional institutional interest at 196.77 times, robust NII participation at 597.21 times, and strong individual investor subscription at 400.84 times, the share price listing expectations remain highly positive.

Utilisation of IPO Proceeds

The proceeds will be utilised for part financing the capital expenditure towards setting up of a new manufacturing unit at Industrial Plot No. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh (₹15.96 crore), funding the working capital requirements of the Company (₹8.25 crore), and general corporate purposes.

Business Overview

Avience Biomedicals Limited is engaged as a medical consumable product manufacturer as well as a trader. It operates in B2B as well as B2C segments providing advanced technology products. The company marked steady growth in its top and bottom lines for the reported periods.

The company demonstrated financial performance with total income of ₹45.97 crore for FY2025 and a net worth of ₹28.52 crore as of January 31, 2026. The company benefits from strong industry experience and expertise, a diverse range of diagnostic products including rapid test kits, analyzers, hematology devices, and molecular kits, a strong distribution network across India with a growing international footprint, cost-effective and affordable solutions, and stringent quality control processes with ISO standards and regulatory approvals. However, investors should note the post-issue P/E ratio of 16.56 and Price to Book Value of 2.94.

Check the latest IPO allotment status to stay informed.